Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita & Nakao Iwata. (2016) A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatric Disease and Treatment 12, pages 3041-3049.
Read now
Read now
Articles from other publishers (25)
Qijing Bo, Xijin Wang, Xuejun Liu, Hong Sang, Zhiyuan Xun, Ruiling Zhang, Xiaodong Yang, Huaili Deng, Keqing Li, Jindong Chen, Meijuan Sun, Guijun Zhao, Xianglai Liu, Duanfang Cai, Guilai Zhan, Juhong Li, Haiyun Li & Gang Wang. (2023) Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance. BMC Psychiatry 23:1.
Crossref
Crossref
Hikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, Jun-ichi Iga, Shinichiro Ochi, Kayo Ichihashi, Ryuji Furihata, Yoshitaka Kyo, Yoshikazu Takaesu, Takashi Tsuboi, Fumitoshi Kodaka, Toshiaki Onitsuka, Tsuyoshi Okada, Atsunobu Murata, Hiroko Kashiwagi, Hitoshi Iida, Naoki Hashimoto, Kazutaka Ohi, Hisashi Yamada, Kazuyoshi Ogasawara, Yuka Yasuda, Hiroyuki Muraoka, Masahide Usami, Shusuke Numata, Masahiro Takeshima, Hirotaka Yamagata, Tatsuya Nagasawa, Hiromi Tagata, Manabu Makinodan, Mikio Kido, Eiichi Katsumoto, Hiroshi Komatsu, Junya Matsumoto, Chika Kubota, Kenichiro Miura, Akitoyo Hishimoto, Koichiro Watanabe, Ken Inada, Hiroaki Kawasaki & Ryota Hashimoto. (2022) Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. Frontiers in Psychiatry 13.
Crossref
Crossref
Chengcheng Pu, Lei Lei, Fude Yang, Hong Deng, Jianhua Sheng, Zhening Liu, Shaohua Hu, Lina Wang, Bin Wu, Qijing Bo, Yoshifumi Inoue & Xin Yu. (2022) Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial. BMJ Open 12:4, pages e054079.
Crossref
Crossref
Kazutaka Ohi, Kentaro Takai, Ayumi Kuramitsu, Shunsuke Sugiyama & Toshiki Shioiri. (2022) Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 113, pages 110470.
Crossref
Crossref
Takuya SaitoSaori SugimotoReiko SakaguchiHiroshi Nakamura & Jun Ishigooka. (2022) Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology 32:1, pages 12-23.
Crossref
Crossref
Sebastiano Alfio Torrisi, Federica Geraci, Gabriella Contarini, Salomone Salomone, Filippo Drago & Gian Marco Leggio. 2023. Therapeutic Applications of Dopamine D3 Receptor Function. Therapeutic Applications of Dopamine D3 Receptor Function
133
156
.
Mitsukuni Murasaki, Yoshifumi Inoue, Hiroshi Nakamura & Toshihiko Kinoshita. (2021) Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies. Annals of General Psychiatry 20:1.
Crossref
Crossref
Shintaro Sakai, Yoshiro Morimoto, Yusuke Matsuzaka, Takeshi Nakano, Shinji Kanegae, Akira Imamura & Hiroki Ozawa. (2021) Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report. Neuropsychopharmacology Reports 41:3, pages 440-443.
Crossref
Crossref
Akihiro Shiina, Tadashi Hasegawa & Masaomi Iyo. (2021) Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report. World Journal of Clinical Cases 9:11, pages 2469-2477.
Crossref
Crossref
Yoshifumi Inoue, Kimiko Tsuchimori & Hiroshi Nakamura. (2021) Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances. Journal of Pharmacological Sciences 145:1, pages 42-51.
Crossref
Crossref
Wataru Ukai, Kenta Deriha, Eri Hashimoto & Chiaki Kawanishi. 2021. The Neuroscience of Depression. The Neuroscience of Depression
369
379
.
Nakao Iwata, Jun Ishigooka, Won-Hyoung Kim, Bo-Hyun Yoon, Shih-Ku Lin, Ahmad Hatim Sulaiman, Rowena Cosca, Lina Wang, Yury Suchkov, Alexey Agarkov, Kei Watabe, Tomohito Matsui, Takayuki Sato, Yoshifumi Inoue, Teruhiko Higuchi, Christoph U. Correll & John M. Kane. (2020) Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophrenia Research 215, pages 408-415.
Crossref
Crossref
Saori Takeuchi, Hirotake Hida, Mizuki Uchida, Ryo Naruse, Akira Yoshimi, Shinji Kitagaki, Norio Ozaki & Yukihiro Noda. (2019) Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochemistry International 128, pages 127-134.
Crossref
Crossref
Philip D. Harvey, Hiroshi Nakamura & Mitsukuni Murasaki. (2019) Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8‐week, double‐blind, multicenter, randomized controlled study. Neuropsychopharmacology Reports 39:3, pages 173-182.
Crossref
Crossref
Amane Tateno, Takeshi Sakayori, Woo-chan Kim, Kazuyoshi Honjo, Haruo Nakayama, Ryosuke Arakawa & Yoshiro Okubo. (2018) Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. International Journal of Neuropsychopharmacology 21:6, pages 522-527.
Crossref
Crossref
Sebastiano Alfio Torrisi, Salvatore Salomone, Federica Geraci, Filippo Caraci, Claudio Bucolo, Filippo Drago & Gian Marco Leggio. (2017) Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 Receptor Blockade. Frontiers in Pharmacology 8.
Crossref
Crossref
Yin Cui, Vishwanath Vasudev Prabhu, Thong Ba Nguyen, Subramaniam Mohana Devi & Young-Chul Chung. (2017) Longer Telomere Length of T lymphocytes in Patients with Early and Chronic Psychosis. Clinical Psychopharmacology and Neuroscience 15:2, pages 146-152.
Crossref
Crossref
Asuka Katsuki, Hikaru Hori, Kiyokazu Atake, Ryohei Igata, Yuki Konishi & Reiji Yoshimura. (2017) A 52-week, randomized, open-label study of aripiprazole versus blonanserin in the treatment of Japanese schizophrenia patients. Clinical Neuropsychopharmacology and Therapeutics 8:0, pages 16-24.
Crossref
Crossref
Ganesh Gopalakrishna, Muaid H. Ithman & John Lauriello. (2016) Update on New and Emerging Treatments for Schizophrenia. Psychiatric Clinics of North America 39:2, pages 217-238.
Crossref
Crossref
Manato Kotani, Takeshi Enomoto, Takeshi Murai, Tomokazu Nakako, Yoshihiro Iwamura, Akihiko Kiyoshi, Kenji Matsumoto, Atsushi Matsumoto, Masaru Ikejiri, Tatsuo Nakayama, Yuji Ogi & Kazuhito Ikeda. (2016) The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets. Behavioural Brain Research 305, pages 212-217.
Crossref
Crossref
Yasuhide Nagoshi, Toshiyuki Tominaga & Kenji Fukui. (2016) Blonanserin Augmentation for Treatment-Resistant Somatic Symptom Disorder. Clinical Neuropharmacology 39:2, pages 112-114.
Crossref
Crossref
Mei Huang, Sunoh Kwon, Yoshihiro Oyamada, Lakshmi Rajagopal, Masanori Miyauchi & Herbert Y. Meltzer. (2015) Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacology Biochemistry and Behavior 138, pages 49-57.
Crossref
Crossref
Ayaka Tatara, Saki Shimizu, Atsushi Masui, Miyuki Tamura, Shoko Minamimoto, Yuto Mizuguchi, Midori Ochiai, Yusuke Mizobe & Yukihiro Ohno. (2015) Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin. Pharmacology Biochemistry and Behavior 138, pages 14-19.
Crossref
Crossref
Satoko Baba, Takeshi Enomoto, Tomoko Horisawa, Takashi Hashimoto & Michiko Ono. (2015) Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. Journal of Pharmacological Sciences 127:3, pages 326-331.
Crossref
Crossref
Pradipbhai D. Kalariya, Prinesh N. Patel, Mahesh Sharma, Prabha Garg, R. Srinivas & M. V. N. Kumar Talluri. (2015) Characterization of stress degradation products of blonanserin by UPLC-QTOF-tandem mass spectrometry. RSC Advances 5:85, pages 69273-69288.
Crossref
Crossref